Inspire Medical Systems (NYSE:INSP) Price Target Raised to $65.00

Inspire Medical Systems (NYSE:INSP) had its target price raised by Mizuho from $55.00 to $65.00 in a report published on Tuesday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

INSP has been the subject of a number of other reports. JPMorgan Chase & Co. reduced their price target on shares of Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating for the company in a research report on Tuesday, May 5th. UBS Group initiated coverage on Inspire Medical Systems in a research report on Tuesday, July 28th. They issued a “sell” rating and a $39.00 price objective on the stock. Bank of America lowered Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price objective for the company. in a research note on Friday, May 22nd. Stifel Nicolaus set a $75.00 price objective on Inspire Medical Systems in a research note on Tuesday. Finally, Truist Financial restated a “hold” rating and set a $62.00 target price (up from $54.00) on shares of Inspire Medical Systems in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $68.00.

Inspire Medical Systems Trading Down 2.0%

INSP stock opened at $58.91 on Tuesday. The firm has a 50 day moving average of $47.26 and a 200-day moving average of $54.48. The firm has a market capitalization of $1.70 billion, a P/E ratio of 12.75, a price-to-earnings-growth ratio of 4.55 and a beta of 0.70. Inspire Medical Systems has a 12 month low of $38.91 and a 12 month high of $147.03.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The business had revenue of $200.58 million for the quarter, compared to analyst estimates of $194.72 million. During the same quarter in the prior year, the firm posted $0.45 EPS. Inspire Medical Systems’s revenue was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Sell-side analysts predict that Inspire Medical Systems will post 1.24 EPS for the current year.

Hedge Funds Weigh In On Inspire Medical Systems

A number of hedge funds and other institutional investors have recently bought and sold shares of INSP. CWM LLC increased its holdings in shares of Inspire Medical Systems by 216.1% in the 4th quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after buying an additional 242 shares during the last quarter. Havemeyer Place LP bought a new stake in shares of Inspire Medical Systems during the 4th quarter worth $39,000. V Square Quantitative Management LLC bought a new stake in shares of Inspire Medical Systems during the 4th quarter worth $40,000. Smartleaf Asset Management LLC grew its position in Inspire Medical Systems by 84.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after acquiring an additional 205 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its position in Inspire Medical Systems by 38.7% in the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock worth $60,000 after acquiring an additional 130 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.